Herbert Bonkovsky to Alanine Transaminase
This is a "connection" page, showing publications Herbert Bonkovsky has written about Alanine Transaminase.
Connection Strength
0.635
-
Russo MW, Hoofnagle JH, Gu J, Fontana RJ, Barnhart H, Kleiner DE, Chalasani N, Bonkovsky HL. Spectrum of statin hepatotoxicity: experience of the drug-induced liver injury network. Hepatology. 2014 Aug; 60(2):679-86.
Score: 0.118
-
Bonkovsky HL. Optimal management of nonalcoholic fatty liver/steatohepatitis. J Clin Gastroenterol. 2003 Mar; 36(3):193-5.
Score: 0.054
-
Bonkovsky HL, Stefancyk D, McNeal K, Banner BF, Liu Q, Zucker GM, Israel J, Stagias J, Colker J. Comparative effects of different doses of ribavirin plus interferon-alpha2b for therapy of chronic hepatitis C: results of a controlled, randomized trial. Dig Dis Sci. 2001 Oct; 46(10):2051-9.
Score: 0.049
-
Fontana RJ, Israel J, LeClair P, Banner BF, Tortorelli K, Grace N, Levine RA, Fiarman G, Thiim M, Tavill AS, Bonkovsky HL. Iron reduction before and during interferon therapy of chronic hepatitis C: results of a multicenter, randomized, controlled trial. Hepatology. 2000 Mar; 31(3):730-6.
Score: 0.044
-
Bonkovsky HL, Woolley JM. Reduction of health-related quality of life in chronic hepatitis C and improvement with interferon therapy. The Consensus Interferon Study Group. Hepatology. 1999 Jan; 29(1):264-70.
Score: 0.041
-
Banner BF, Karamitsios N, Smith L, Bonkovsky HL. Enhanced phenotypic expression of alpha-1-antitrypsin deficiency in an MZ heterozygote with chronic hepatitis C. Am J Gastroenterol. 1998 Sep; 93(9):1541-5.
Score: 0.040
-
Banner BF, Allan C, Smith L, Savas L, Bonkovsky HL. Effect of interferon therapy on bile duct inflammation in hepatitis C. Virchows Arch. 1996 Jul; 428(4-5):253-9.
Score: 0.034
-
deLemos AS, Ghabril M, Rockey DC, Gu J, Barnhart HX, Fontana RJ, Kleiner DE, Bonkovsky HL. Amoxicillin-Clavulanate-Induced Liver Injury. Dig Dis Sci. 2016 08; 61(8):2406-2416.
Score: 0.034
-
Bonkovsky HL, Clifford BD, Smith LJ, Allan C, Banner B. High-dose interferon-alpha 2b for re-treatment of nonresponders or relapsing patients with chronic hepatitis C. A controlled randomized trial. Dig Dis Sci. 1996 Jan; 41(1):149-54.
Score: 0.033
-
Banner BF, Barton AL, Cable EE, Smith L, Bonkovsky HL. A detailed analysis of the Knodell score and other histologic parameters as predictors of response to interferon therapy in chronic hepatitis C. Mod Pathol. 1995 Apr; 8(3):232-8.
Score: 0.031
-
Chalasani N, Vuppalanchi R, Navarro V, Fontana R, Bonkovsky H, Barnhart H, Kleiner DE, Hoofnagle JH. Acute liver injury due to flavocoxid (Limbrel), a medical food for osteoarthritis: a case series. Ann Intern Med. 2012 Jun 19; 156(12):857-60, W297-300.
Score: 0.026
-
O'Bryan JM, Potts JA, Bonkovsky HL, Mathew A, Rothman AL. Extended interferon-alpha therapy accelerates telomere length loss in human peripheral blood T lymphocytes. PLoS One. 2011; 6(8):e20922.
Score: 0.024
-
Freedman ND, Everhart JE, Lindsay KL, Ghany MG, Curto TM, Shiffman ML, Lee WM, Lok AS, Di Bisceglie AM, Bonkovsky HL, Hoefs JC, Dienstag JL, Morishima C, Abnet CC, Sinha R. Coffee intake is associated with lower rates of liver disease progression in chronic hepatitis C. Hepatology. 2009 Nov; 50(5):1360-9.
Score: 0.022
-
Ghany MG, Lok AS, Everhart JE, Everson GT, Lee WM, Curto TM, Wright EC, Stoddard AM, Sterling RK, Di Bisceglie AM, Bonkovsky HL, Morishima C, Morgan TR, Dienstag JL. Predicting clinical and histologic outcomes based on standard laboratory tests in advanced chronic hepatitis C. Gastroenterology. 2010 Jan; 138(1):136-46.
Score: 0.021
-
Di Bisceglie AM, Shiffman ML, Everson GT, Lindsay KL, Everhart JE, Wright EC, Lee WM, Lok AS, Bonkovsky HL, Morgan TR, Ghany MG, Morishima C, Snow KK, Dienstag JL. Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl J Med. 2008 Dec 04; 359(23):2429-41.
Score: 0.020
-
Di Bisceglie AM, Sterling RK, Chung RT, Everhart JE, Dienstag JL, Bonkovsky HL, Wright EC, Everson GT, Lindsay KL, Lok AS, Lee WM, Morgan TR, Ghany MG, Gretch DR. Serum alpha-fetoprotein levels in patients with advanced hepatitis C: results from the HALT-C Trial. J Hepatol. 2005 Sep; 43(3):434-41.
Score: 0.016
-
Lok AS, Ghany MG, Goodman ZD, Wright EC, Everson GT, Sterling RK, Everhart JE, Lindsay KL, Bonkovsky HL, Di Bisceglie AM, Lee WM, Morgan TR, Dienstag JL, Morishima C. Predicting cirrhosis in patients with hepatitis C based on standard laboratory tests: results of the HALT-C cohort. Hepatology. 2005 Aug; 42(2):282-92.
Score: 0.016
-
Di Bisceglie AM, Bonkovsky HL, Chopra S, Flamm S, Reddy RK, Grace N, Killenberg P, Hunt C, Tamburro C, Tavill AS, Ferguson R, Krawitt E, Banner B, Bacon BR. Iron reduction as an adjuvant to interferon therapy in patients with chronic hepatitis C who have previously not responded to interferon: a multicenter, prospective, randomized, controlled trial. Hepatology. 2000 Jul; 32(1):135-8.
Score: 0.011